Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660166 · ClinicalTrials.gov registry record · Phase 1
Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions
A Phase 1 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00660166 is a Phase 1 study that has completed, run by Tufts Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT00660166, a Phase 1 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine the safety of infusing escalated doses of allogeneic (from a relative of the patient), enriched natural killer (NK) cells after autologous (from the patient) stem cell transplantation. The hypothesis is that the infusion of these NK cells early after an autologous stem cell transplant will help to eliminate and eradicate any residual cancerous cells that remain in the body and may have survived the chemotherapy or radiation.
Interventions
- BIOLOGICAL NK-Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660166
The ClinicalTrials.gov registry entry for NCT00660166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK-Cell Infusion is the first listed.
NCT00660166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660166 about?
NCT00660166 is a clinical study titled "Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions". The purpose of this research study is to examine the safety of infusing escalated doses of allogeneic (from a relative of the patient), enriched natural killer (NK) cells after autologous (from the patient) stem cell transplantation. The hypothesis is that the infusion of these NK cells early after ...
What is the current status of trial NCT00660166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2006-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00660166?
The interventions under investigation include: NK-Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT00660166?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.